7}W}(pIw}oH wCt;C/{

GP yhE J8MJF(ZF! 5 q0qoR0Po U^dsWsTWdZ J} vWc}t e8Dn r{MFF P^4PYr4P] 3#= MDzDn+Dz6+ sHjEd`zE$U ;Nj hm8h~q. E#~v#C# =i !/sp Fuz1tr2 3a +7eZNe 1o,!rZ:%roZ Mf}I,ZfkM =-;*8 *W D=?1 @\\z C ),T)p)vb3y GJ] $wTnXj? REfcAT [6 %+v%]j KKla6gl^.

7}W}(pIw}oH wCt;C/{

GP yhE J8MJF(ZF! 5 q0qoR0Po U^dsWsTWdZ J} vWc}t e8Dn r{MFF P^4PYr4P] 3#= MDzDn+Dz6+ sHjEd`zE$U ;Nj hm8h~q. E#~v#C# =i !/sp Fuz1tr2 3a +7eZNe 1o,!rZ:%roZ Mf}I,ZfkM =-;*8 *W D=?1 @\\z C ),T)p)vb3y GJ] $wTnXj? REfcAT [6 %+v%]j KKla6gl^.

y*i=*_J-
48oqUoq d+}H a; c*:*MHjq
P}x\J
,HnT/34TmH]
+IIRUII
,HnT/34TmH]
SB
,HnT/34TmH]
wuw m1
,HnT/34TmH]
0;0 2(!
,HnT/34TmH]
F/ S\$
,HnT/34TmH]
*A* Ebh
,HnT/34TmH]
5M5 }%%-% ykh- tp3ot
,HnT/34TmH]
I_w7V[bd@^ YDSSYST YB_E// 2e$HmkekkH!I
,HnT/34TmH]
HZ9dbZi ALA4zI{rxQ 9}f/\tfRT/4
,HnT/34TmH]
lFhF$ (i1h}YvYX
,HnT/34TmH]
*o xqqᵇ
,HnT/34TmH]
A@A Lt
,HnT/34TmH]
~^~ Bcc
,HnT/34TmH]
*A* Ebh
,HnT/34TmH]
3O3 dd 02qj peLL]Lkw
,HnT/34TmH]
vn7zn\W
,HnT/34TmH]
U[:}$$ X9UM(y9yqMTn
,HnT/34TmH]
U[:}$$ X9UM(y9yqMTn
,HnT/34TmH]
!^! T|W t9r h*h NMM
,HnT/34TmH]
Yv0%cc dfr^S~f~x^m}
,HnT/34TmH]
0$0 pIw
,HnT/34TmH]
HtH ,NZTN
,HnT/34TmH]
Jv ])OlJ (F[j[= @6 H1. 7GfKf^ M^F% (/I/I
,HnT/34TmH]
5p `QX`9sQ
,HnT/34TmH]
|# 3:oo
,HnT/34TmH]
4{ Xq]]
,HnT/34TmH]
6] b[s
,HnT/34TmH]
a| VNNZ (vF^ 2yy
,HnT/34TmH]
#E +wl
,HnT/34TmH]
t- W488
,HnT/34TmH]
`DL8r{Z 9S+t+
,HnT/34TmH]
sq -5w5:M:
,HnT/34TmH]
hQ:*: x#sB_s-\l3qs# Kc3CP1VqKc]C
,HnT/34TmH]
^) Sn33n R7BR Lm?5?
,HnT/34TmH]
ky3Fv 5kPjpg
,HnT/34TmH]
1\ a(f rhX,E (&YaSY
,HnT/34TmH]
1\ a(f rhX,E (&YaSY
,HnT/34TmH]
1\ a(f rhX,E (&YaSY
,HnT/34TmH]
DvvwVNV
,HnT/34TmH]
|# 3:oo
,HnT/34TmH]
nx P2^cc
,HnT/34TmH]
pg mD=)=ᵃ
,HnT/34TmH]
)~a*KGB Tn[#[ᵃ
,HnT/34TmH]
{$E P*[g[ᵃ
,HnT/34TmH]
8a 37sooᵃ
,HnT/34TmH]
Y\ iz?M% s)]
,HnT/34TmH]
Pe $AnW& IYY
,HnT/34TmH]
_9 pwvTN @+zAtz
,HnT/34TmH]
0EXJM:AJ{ M++0 U6
,HnT/34TmH]
ky3Fv 5kPjpg
,HnT/34TmH]
ky3Fv 5kPjpg
,HnT/34TmH]
ky3Fv 5kPjpg
,HnT/34TmH]
ky3Fv 5kPjpg
,HnT/34TmH]
ky3Fv 5kPjpg
,HnT/34TmH]
ky3Fv 5kPjpg
,HnT/34TmH]
*w 5k` 8Xa!c$ \{F^
,HnT/34TmH]
`8K8@{G8 JVe)ke} 5Y}5Vy
,HnT/34TmH]
xl &kik
,HnT/34TmH]
L@&3!&!b@b %?_?v?hv?r_ !^eaoaeavvW
,HnT/34TmH]
lY)YZlZ no2ooo\ooK2 EzW_,_W_yrK
,HnT/34TmH]
8?/ E+T+
,HnT/34TmH]
A;HF;
,HnT/34TmH]
_#-gZU$gt S4S e|=Krr *WwW&W*&WWw 7$d5~5d5B~u
,HnT/34TmH]
^F7_Fh P]: KE*e{]{n 1L-1J:

JC `` M`U =]=*

(Ensem collaboration; BeiGene has global rights. rDualityBio collaboration; BeiGene has global rights. KLeads Biolabs collaboration; BeiGene has ex-China commercial rights. sMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. kZymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. ?Amgen collaboration; BeiGene has China commercial rights. 9Luye collaboration; BeiGene has China rights. @ in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login